BofA Securities analysts reaffirmed a Buy rating for Eli Lilly (NYSE:LLY) with a price target on the stock of $997. The company stands out as a premier opportunity within the large-cap biopharma ...
A law that coaxed companies to lower the price of drugs came with a little-known consequence: smaller discounts for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback